Abstract
Background Brucellosis is both endemic and enzootic in Iraq, resulting in long-term morbidity for humans as well as economic loss. No previous study of the spatial and temporal patterns of brucellosis in Iraq was done to identify potential clustering of cases.
Objectives This study aims to detect the spatial and temporal distribution of human brucellosis in Iraq and identify any changes that occurred from 2007 to 2018.
Methods A descriptive cross-sectional study using secondary data from the Communicable Diseases Control Center / Ministry of Health surveillance section. We used Moran’s I, local Getis-Ord’s Gi*, and the local indicators of spatial association (LISA) to detect the spatial distribution of the data. The data was analyzed using Excel software and the Quantum GIS (QGIS) version 2.18.20 (Steiniger and Hunter, 2013).
Results 50,621 human brucellosis cases were reported during the 12-year study period. Human brucellosis persisted annually in Iraq across the study period with no specific temporal clustering of cases. In contrast, spatial clustering was predominant in the Northern region of Iraq.
Conclusion There were significant differences in the geographic distribution of brucellosis. The number of cases is highest in the north and northeast of the country, which has borders with nearby countries. In addition, people in these areas depend more on locally made dairy products, which can be inadequately pasteurized. Despite the lack of significant temporal clustering of cases, the highest number of cases were reported during Summer and Spring.
Recommendations Considering these patterns when allocating resources to combat this disease, determining public health priorities, and planning prevention and control strategies is important.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Administrative and ethical approval was granted from the Public Health Directorate/Iraq MOH.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
E.Mail alihazim001122{at}gmail.com
email: drhanan.cdcciq{at}gmail.com
email: farislami{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
